A joint technical session with enGenes Biotech and NorthX Biologics on closing the gap for translation from preclinical to clinical phase by the application of high performing E.coli expression technology in an aligned and derisked end to end workflow. Every month lost before an IND/IMPD-enabling GMP batch is a month of runway putting increased pressure on the program.. Many delays don’t originate in the science itself – they happen in the handovers between expression development, process optimization, and manufacturing. Every transition introduces complexity, risk, and the potential for costly delays. In this webinar, enGenes Biotech and NorthX Biologics will explore how a fully integrated E. coli development pathway can help reduce these bottlenecks and create a more efficient route from gene to GMP.
📅 Date: September 30, 2026
⏰ Time: 15:00 CEST / 09:00 EDT
⏱ Duration: ~40 minutes (including live Q&A)
🎤 Speakers: Ola Tuvesosson, NorthX Biologics & Jürgen Mairhofer, enGenes
